- Home
- RNA vs CRSP Comparison
RNA vs CRSP Comparison
Compare RNA & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- CRSP
- Stock Information
- Founded
- RNA 2012
- CRSP 2013
- Country
- RNA United States
- CRSP Switzerland
- Employees
- RNA N/A
- CRSP N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNA Health Care
- CRSP Health Care
- Exchange
- RNA Nasdaq
- CRSP Nasdaq
- Market Cap
- RNA 3.7B
- CRSP 3.4B
- IPO Year
- RNA 2020
- CRSP 2016
- Fundamental
- Price
- RNA $29.52
- CRSP $34.03
- Analyst Decision
- RNA Strong Buy
- CRSP Buy
- Analyst Count
- RNA 12
- CRSP 19
- Target Price
- RNA $68.25
- CRSP $74.35
- AVG Volume (30 Days)
- RNA 1.4M
- CRSP 1.7M
- Earning Date
- RNA 05-08-2025
- CRSP 05-07-2025
- Dividend Yield
- RNA N/A
- CRSP N/A
- EPS Growth
- RNA N/A
- CRSP N/A
- EPS
- RNA N/A
- CRSP N/A
- Revenue
- RNA $10,897,000.00
- CRSP $37,314,000.00
- Revenue This Year
- RNA N/A
- CRSP $49.76
- Revenue Next Year
- RNA $230.08
- CRSP $275.55
- P/E Ratio
- RNA N/A
- CRSP N/A
- Revenue Growth
- RNA 13.98
- CRSP N/A
- 52 Week Low
- RNA $21.56
- CRSP $33.00
- 52 Week High
- RNA $56.00
- CRSP $68.39
- Technical
- Relative Strength Index (RSI)
- RNA 43.70
- CRSP 28.87
- Support Level
- RNA $30.12
- CRSP $40.41
- Resistance Level
- RNA $33.13
- CRSP $42.72
- Average True Range (ATR)
- RNA 2.14
- CRSP 1.74
- MACD
- RNA -0.05
- CRSP -0.78
- Stochastic Oscillator
- RNA 11.94
- CRSP 9.04
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.